APAC Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Analysis on Size, Share, Trends and Growth Forecast (2024 to 2029)

Updated On: June, 2024
ID: 5075
Pages: 145

Asia Pacific Gastroparesis Drugs Market Size ( 2024 to 2029)

The size of the Asia Pacific Gastroparesis Drugs market was around USD 1.16 Billion in 2024. It is expected to grow at a CAGR of 5.5% to reach USD 1.52 billion by 2029. It captures 20% of the global market.

Y-O-Y rise in the incidence rate of diabetes population, an increase in the number of surgical procedures, and an increase in the geriatric population in the APAC region are primarily fueling the growth rate of the APAC gastroparesis drugs market. In addition, continuous adoption of gastroparesis treatments is another factor accelerating the market's growth. Furthermore, Prokinetics drug is expected to aid in developing the gastroparesis drug market by increasing the frequency of contractions and improving gastrointestinal motility.

Furthermore, the rising prevalence of diabetic Mellitus in the Asia Pacific is driving up demand for diagnostic and treatment, and diabetes is a prominent cause of gastroparesis, propelling the gastroparesis medicine market forward. One of the other key factors is that gastroparesis is on the rise, as this is a highly prevalent type of gastroparesis with no known etiology and symptoms of vomiting, nausea, upper abdominal pain. Dietary changes, antiemetic medicine therapy, prokinetics medication, and symptoms modulators can all help to alleviate these symptoms.

It impairs regular digestion, induces vomiting, and causes blood sugar and nutrition issues, and gastroparesis is treated with various pharmaceuticals and treatments, including reglan, erythromycin, antiemetics, and others. This boosts demand for these treatments and, to some extent, the overall market.

However, side effects from gastroparesis medications, a lengthy regulatory process for therapeutic approval, and difficulties in diagnosing gastroparesis may impede the market. The lack of scientific data on the improvement delivered by prescription medications and the end of clinical trials further impose a negative impact on the gastroparesis drugs market in the APAC region.

This research report on the Asia Pacific Gastroparesis Drugs market has been segmented and sub-segmented into the following categories.

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, Asia Pacific is the fastest-growing market and is anticipated to remain in the forecast period. Emerging economies of India and China are spearheading this growth spurt. According to the Centers for Disease Control and Prevention, over 84 million Americans had prediabetes in 2019, resulting in a high prevalence of gastroparesis and regionally driving the gastroparesis medicine market.  Additionally, rising healthcare expenditures, an increase in the number of hospitals, and the presence of well-established healthcare infrastructure are also contributing to the overall regional market's growth.

Many market participants find the Asia-Pacific region to be a lucrative prospect, as nations such as India have a high prevalence rate of diabetes, which leads to gastroparesis conditions and will contribute to the gastroparesis medicine market. Furthermore, during the forecast period, a surge in demand for user-friendly medicine development, increased healthcare infrastructure, and creative marketing initiatives by leading vendors in growing nations such as India, China, and Japan are projected to present profitable prospects for market expansion.

KEY MARKET PLAYERS:

Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma is a few of the prominent companies in the gastroparesis drugs market in the APAC region.

Please wait. . . . Your request is being processed

Anil Kumar P is research manager at Market Data Forecast and responsible for Healthcare Domain.

Author

Anil Kumar P (Research Manager - Healthcare)

Anil Kumar P is the lead author of this report and the manager of the team responsible for authoring healthcare reports at Market Data Forecast. He holds a Bachelor’s degree in Pharmacy (Hons.) from BITS Pilani, one of India’s premier institutions. Over the past seven years, Anil has gained extensive experience working with multiple market research companies, where he has collaborated with a diverse range of clients—from innovative startups to Fortune 500 companies—delivering data-driven insights and strategic advice that drive business growth.

Read More

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample